DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Get Rating) was the target of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totalling 2,780,000 shares, a decrease of 23.2% from the April 15th total of 3,620,000 shares. Currently, 1.3% of the shares of the company are sold short. Based on an average daily volume of 2,440,000 shares, the short-interest ratio is presently 1.1 days.
In other DENTSPLY SIRONA news, Director Eric Brandt sold 6,900 shares of the stock in a transaction on Tuesday, May 3rd. The stock was sold at an average price of $39.71, for a total transaction of $273,999.00. Following the completion of the transaction, the director now directly owns 35,155 shares of the company’s stock, valued at $1,396,005.05. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.69% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in DENTSPLY SIRONA by 2.8% in the 3rd quarter. Geode Capital Management LLC now owns 4,061,180 shares of the medical instruments supplier’s stock worth $235,146,000 after acquiring an additional 109,108 shares during the last quarter. Invesco Ltd. raised its stake in DENTSPLY SIRONA by 12.9% during the 3rd quarter. Invesco Ltd. now owns 3,969,998 shares of the medical instruments supplier’s stock valued at $230,459,000 after buying an additional 454,358 shares during the last quarter. Gabelli Funds LLC raised its stake in DENTSPLY SIRONA by 118.8% during the 3rd quarter. Gabelli Funds LLC now owns 151,000 shares of the medical instruments supplier’s stock valued at $8,766,000 after buying an additional 82,000 shares during the last quarter. Ensign Peak Advisors Inc raised its stake in DENTSPLY SIRONA by 27.8% during the 3rd quarter. Ensign Peak Advisors Inc now owns 45,684 shares of the medical instruments supplier’s stock valued at $2,652,000 after buying an additional 9,934 shares during the last quarter. Finally, Westpac Banking Corp raised its stake in DENTSPLY SIRONA by 4.5% during the 4th quarter. Westpac Banking Corp now owns 23,388 shares of the medical instruments supplier’s stock valued at $1,305,000 after buying an additional 999 shares during the last quarter. Institutional investors own 94.79% of the company’s stock.
DENTSPLY SIRONA (NASDAQ:XRAY – Get Rating) last released its earnings results on Tuesday, May 10th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.04). DENTSPLY SIRONA had a net margin of 8.81% and a return on equity of 11.63%. The business had revenue of $9.67 billion for the quarter, compared to analysts’ expectations of $982.05 million. During the same quarter in the previous year, the business posted $0.72 earnings per share. DENTSPLY SIRONA’s revenue for the quarter was up 841.1% on a year-over-year basis. As a group, sell-side analysts forecast that DENTSPLY SIRONA will post 2.41 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, April 8th. Investors of record on Friday, March 25th were issued a $0.125 dividend. This is a positive change from DENTSPLY SIRONA’s previous quarterly dividend of $0.11. This represents a $0.50 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date was Thursday, March 24th. DENTSPLY SIRONA’s payout ratio is presently 29.59%.
A number of research firms have recently commented on XRAY. TheStreet lowered DENTSPLY SIRONA from a “b-” rating to a “c+” rating in a report on Friday, March 18th. HC Wainwright lowered their price objective on DENTSPLY SIRONA from $58.00 to $48.00 and set a “hold” rating on the stock in a research report on Friday, April 22nd. Robert W. Baird downgraded DENTSPLY SIRONA from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $67.00 to $48.00 in a research report on Tuesday, April 19th. William Blair downgraded DENTSPLY SIRONA from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 19th. Finally, Barrington Research lowered their price target on DENTSPLY SIRONA from $53.00 to $51.00 in a research report on Wednesday, May 11th. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $52.89.
DENTSPLY SIRONA Company Profile (Get Rating)
DENTSPLY SIRONA Inc designs, develops, manufactures, distributes, and sells various dental products and technologies for professional dental market worldwide. It offers dental equipment, including treatment centers, imaging equipment, motorized dental handpieces, and other instruments; imaging equipment; treatment centers comprising basic dentist chairs, sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, and specialist centers; and lab equipment, such as amalgamators, mixing machines, and porcelain furnaces.
- Get a free copy of the StockNews.com research report on DENTSPLY SIRONA (XRAY)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.